These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36063666)

  • 1. Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.
    Sun Y; Wang L; Sun Y; Wang J; Xue Y; Wu T; Yin W; Qin Q; Sun Y; Wang H; Gao Y; Yang H; Zhao D; Cheng M
    Eur J Med Chem; 2022 Dec; 243():114714. PubMed ID: 36063666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.
    Sun Y; Sun Y; Wang L; Wu T; Yin W; Wang J; Xue Y; Qin Q; Sun Y; Yang H; Zhao D; Cheng M
    Eur J Med Chem; 2022 Aug; 238():114424. PubMed ID: 35576702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of a potent PLK4 inhibitor WY29 with 1H-pyrazolo[3,4-d]pyrimidine scaffold.
    Wang L; Sun Y; Wang J; Xue Y; Sun Y; Qin Q; Sun Y; Zhao D; Cheng M
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200490. PubMed ID: 36442843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
    Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
    Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
    J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
    Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
    Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models.
    Qiao X; Zheng K; Ye L; Yang J; Cui R; Shan Y; Li X; Li H; Zhu Q; Zhao Z; Ge RS; Wang Y
    Br J Pharmacol; 2024 Nov; 181(22):4658-4676. PubMed ID: 39142876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of novel pyrimidin-2-amine derivatives as potent PLK4 inhibitors.
    Xue Y; Mu S; Sun P; Sun Y; Liu N; Sun Y; Wang L; Zhao D; Cheng M
    RSC Med Chem; 2023 Sep; 14(9):1787-1802. PubMed ID: 37731702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of targeting polo-like kinase 4.
    Lei Q; Yu Q; Yang N; Xiao Z; Song C; Zhang R; Yang S; Liu Z; Deng H
    Eur J Med Chem; 2024 Feb; 265():116115. PubMed ID: 38199166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer.
    Hu S; Jiang C; Gao M; Zhang D; Yao N; Zhang J; Jin Q
    Eur J Med Chem; 2023 May; 253():115334. PubMed ID: 37037136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
    Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia.
    Sun Y; Xue Y; Liu H; Mu S; Sun P; Sun Y; Wang L; Wang H; Wang J; Wu T; Yin W; Qin Q; Sun Y; Yang H; Zhao D; Cheng M
    J Med Chem; 2023 Feb; 66(4):2396-2421. PubMed ID: 36734825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
    Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
    Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
    Lim J; Kelley EH; Methot JL; Zhou H; Petrocchi A; Chen H; Hill SE; Hinton MC; Hruza A; Jung JO; Maclean JK; Mansueto M; Naumov GN; Philippar U; Raut S; Spacciapoli P; Sun D; Siliphaivanh P
    J Med Chem; 2016 Jul; 59(13):6501-11. PubMed ID: 27329786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
    Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
    Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent.
    Qi B; Wang F; He H; Fan M; Hu L; Xiong L; Gong G; Shi S; Song X
    Eur J Med Chem; 2022 Sep; 239():114561. PubMed ID: 35763868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
    Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
    Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.